Results 11 to 20 of about 38,154 (222)

Efficacy and Toxicity of Factor Xa Inhibitors

Journal of Pharmacy & Pharmaceutical Sciences, 2013
Venous thromboembolism (VTE) is a serious disease that is often neglected, and effective and safe antithrombotic treatments are a public health priority.
Maryna Bondarenko, Christophe Curti, Marc Montana, Pascal Rathelot, Patrice Vanelle   +4 more
doaj   +5 more sources

Three cases of neutralization of factor Xa inhibitors with andexanet alfa under rotational thromboelastography monitoring. [PDF]

Acute Med Surg
Background Factor Xa inhibitors are direct oral anticoagulants that are extremely useful in clinical applications, safe, and do not require dose adjustment.
Yagi T, Kawano R, Tomokage T, Ayata R, Koga Y, Kaneda K, Fujita M, Yamanaka N, Mori N, Tsuruta R.   +9 more
europepmc   +2 more sources

Factor Xa inhibitor for venous thromboembolism management in patient with cancer: a systematic review and meta-analysis [version 1; peer review: 2 approved]

F1000Research, 2021
Background: An earlier systematic review reported no differences in the incidence of recurrent venous thromboembolism and major bleeding between factor Xa inhibitors and standard anticoagulation.
Ardyan Wardhana, Johanes Nugroho Eko Putranto, Pirhot Lambok Marnala Yosua Siahaan, Yoga Alfian Noor, Makhyan Jibril Al Farabi   +4 more
doaj   +1 more source

Efficacy of Factor Xa Inhibitors Versus Placebo in Thromboprophylaxis for Cancer-Associated Thromboembolism: A Systematic Review and Meta-analysis. [PDF]

Clin Appl Thromb Hemost
Background Cancer patients are at significantly increased risk of venous thromboembolism (VTE), a leading cause of morbidity and mortality in this population.
Kamil A, Kumar SP, Zulfiqar R, Araib E, Khan BS, Khan MS, Khan MM, Naeem U, Waafira A.   +8 more
europepmc   +2 more sources

Recommendations for the use of andexanet alfa in the management of bleeding in patients on oral factor Xa inhibitors in Switzerland

Swiss Medical Weekly, 2023
Anticoagulants are essential in preventing and treating thrombosis. Unfortunately, their use is accompanied by an enhanced risk of bleeding. Since the introduction of direct oral anticoagulants (DOACs), the risk of major bleeding has been reduced but ...
Anne Angelillo-Scherrer, Alessandro Casini, Jan-Dirk Studt, Bernhard Gerber, Lorenzo A. Alberio, Pierre Fontana   +5 more
doaj   +1 more source

Direct factor Xa inhibitors and the risk of cancer and cancer mortality: A Danish population-based cohort study. [PDF]

PLoS Med
BackgroundPreclinical animal studies have suggested that myeloid cell-synthesized coagulation factor X dampens antitumor immunity and that rivaroxaban, a direct factor Xa inhibitor, can be used to promote tumor immunity. This study was aimed at assessing
Bosch F, Horváth-Puhó E, Cannegieter SC, van Es N, Sørensen HT.   +4 more
europepmc   +2 more sources

Monitoring anti-factor Xa activity in patients with chronic thromboembolic pulmonary hypertension treated with factor Xa inhibitors. [PDF]

Sci Rep
Direct oral anticoagulants (DOACs) have been used clinically in patients with chronic thromboembolic pulmonary hypertension (CTEPH) for secondary prevention after acute venous thromboembolism, although the data are limited.
Nakano Y, Adachi S, Hirose M, Adachi T, Nishiyama I, Yasuda K, Yoshida M, Kondo T, Murohara T.   +8 more
europepmc   +2 more sources

Prediction of inhibition constants of (R)-3-amidinophenylalanine inhibitors toward factor Xa by 2D-QSAR model

Vietnam Journal of Science, Technology and Engineering, 2022
A coagulation cascade forms through proteolytic reactions and involves different factors. There are two coagulation pathways, including intrinsic and extrinsic mechanisms, which converge by the formation of factor Xa.
Thi Bich Van Pham, Minh Hao Hoang
doaj   +1 more source

Warfarin versus factor Xa inhibitors in the long-term treatment of cerebral venous sinus thrombosis a single-center retrospective analysis

eNeurologicalSci, 2022
Long-term anticoagulation in the treatment of Cerebral Venous Sinus Thrombosis (CVST) has revolved around the use of warfarin. The relatively recent introduction of Direct Oral Anticoagulants (DOACs), such as Factor Xa inhibitors, in treating CVSTs ...
Alexei Christodoulides, Bradley N. Bohnstedt   +1 more
doaj   +1 more source

Allosteric Inhibition of Factor XIIIa. Non-Saccharide Glycosaminoglycan Mimetics, but Not Glycosaminoglycans, Exhibit Promising Inhibition Profile [PDF]

, 2016
Factor XIIIa (FXIIIa) is a transglutaminase that catalyzes the last step in the coagulation process. Orthostery is the only approach that has been exploited to design FXIIIa inhibitors.
Afosa, Daniel K., Al-Horani, Rami A., Desai, Umesh R., Karuturi, Rajesh, Lee, Michael   +4 more
core   +8 more sources